| Next 10 |
Ad
IMMX News and Press Immix Biopharma Inc.
News | Immix Biopharma Inc. (NASDAQ:IMMX)
-
U.S. engineering batches support planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the United States Engineering batches are the first step in transferring the Company’s existing CAR-T GMP manufacturing process to the United States Commenceme...
-
2023-05-26 08:31:34 ET SunCar Technology Group ( SDA ) -27% . Wearable Devices ( WLDS ) -26% . Tilray Brands ( TLRY ) -22% follows $150M convertible note offering . Nano Labs ( NA ) -16% . Beamr Imaging ( BMR ) -15% . HEXO ( ...
-
2023-05-23 08:45:00 ET Biocept ( BIOC ) 10% . Microvast Holdings ( MVST ) -20% plunges as Energy Department said to cancel DoE contract. Wave Life Sciences ( WVE ) -13% crashes on decision to drop neurology asset on trial setback. ToughBuilt I...
-
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5/8) complete response (MRD 10 -5 ) was demonstrated by NXC-201 with zero ICANs, zero grade 4 CRS 62% (5/8) had NYHA classificat...
-
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5/8) complete response (MRD 10 -5 ) was demonstrated by NXC-201 with zero ICANs, zero grade 4 CRS 62% (5/8) had NYHA classification ...
-
LOS ANGELES, May 04, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that updated NXC-201 clinical data has been selected for presentation at the upcoming 26th Annual Meetin...
-
2023-05-03 09:05:24 ET Immix Biopharma ( NASDAQ: IMMX ) reported early interim data from a phase 1b/2a trial of IMX-110 in combination with Novartis ( NYSE: NVS ) and BeiGene's ( NASDAQ: BGNE ) tislelizumab to treat patients with advanced metastatic co...
-
2023-05-03 08:28:28 ET Guardforce AI GFAI -60% raises $8M through equity offering priced at $4.65, shares down 58%. VCI Global Limited ( VCIG ) -50% . Actelis Networks ( ASNS ) -45% . Leju Holdings Limited ( LEJU ) -30% . Minim ( MINM ) ...
-
100% Tumor Shrinkage at 2-months in advanced metastatic colorectal cancer was demonstrated by IMX-110 + BeiGene / Novartis anti-PD-1 Antibody Tislelizumab combination in the first, lowest dose cohort (two out of two first evaluable patients) in its ongoing phase 1b/2a dose escalation clinical tri...
-
2023-04-27 12:24:19 ET Gainers: TOP Financial Group Limited ( TOP ) +186% . Evelo Biosciences ( EVLO ) +184% . ContraFect Corporation ( CFRX ) +68% . U Power Limited Ordinary Shares ( UCAR ) +40% . Atomera Incorporated ( ATOM ) +33...
Stock Information
Trending Stock
9.38%Change Percent:
Immix Biopharma Inc. Company Name:
IMMX Stock Symbol:
NASDAQ Market:
Get IMMX Alerts
News, Short Squeeze, Breakout and More Instantly...
Ad
